pharmaphorum14h
Sanofi wins appeal in spat with NICE over Sarclisa
Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...
The Pharma Letter14h
UK looks again at Sarclisa for myeloma as demand grows
Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...
pharmaphorum14h
Coming soon: The Life Sciences Industry Report 2025 – insights and predictions you won’t want to miss
Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...
FiercePharma5d
J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
FiercePharma5d
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...